Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients

British Journal of Cancer

Volumn 80, Issue 5-6, 1999, Pages 892-897

  Salgado, R ^a   Vermeulen, P B ^a,b   Benoy, I ^a   Weytjens, R ^a   Huget, P ^a   Van Marck, E ^a,b   Dirix, L Y ^a  

^a Oncology Centre of Antwerp   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Angiogenesis; Blood platelets; Interieukin 6; VEGF

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; INTERLEUKIN 6; VASCULOTROPIN;

ADVANCED CANCER; ANGIOGENESIS; ARTICLE; BLOOD CLOTTING; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MITOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTE COUNT; THROMBOCYTOPOIESIS; TUMOR GROWTH;

EID: 0032925155     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690437     Document Type: Article

References (44)

1. Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C and Selby PJ (1998) Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 77: 956-964
2. Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF and Philip T (1992) Serum levels of interleukin 6 as a prognostic factor in metastatic renal cell carcinoma. Cancer Res 52: 3317-3322
3. Bousvaros A, Zurakowski D, Fishman SJ, Keough K, Law T, Sun C and Leichter AM (1997) Serum basic fibroblast growth factor in pediatric Crohn's disease. Implications for wound healing. Dig Dis Sci 42: 378-386
4. Brekken RA, Huang X, King SW and Thorpe PE (1998.) Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res 58: 1952-1959
5. Bross DA, Leichtner AM, Zurakowski D, Law T and Bousvaros A (1996) Elevation of serum interleukin-6 but not serum-soluble interleukin-2 receptor in children with Crohn's disease. J Pediatr Gastroenterol Nutr 23: 164-171
6. Clarke D, Johnson PWM, Banks RE, Storr M, Kinsey SE, Johnson R, Morgan G, Gordon MY, Illingworth JM, Perren TJ and Selby PJ (1996) Cytokine 8: 717-723
7. Cohen T, Nahari D, Weiss Cerem L, Neufeld G and Levi B (1996) Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 271: 736-741
8. Degeorges A, Tatoud R, Fauvel-Lafeve F, Podgomiak M-P, Millot G, De Cremoux P and Calvo F (1996) Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6. Int J Cancer 68: 207-214
9. Duensig S, Grosse J and Atzpodien J (1995) Increased serum levels of basic fibroblast growth factor (bFGF) are associated with progressive lung metastases in advanced renal cell carcinoma patients. Anticancer Res 15: 2331-2334
10. Dvorak HF (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315: 1650-1659
11. Dirix LY, Vermeulen PB, Hubens G, Benoy I, Martin M, De Pooter C and Van Oosterom AT (1996) Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann Oncol 7: 843-848
12. Dirix LY, Vermeulen PB, Pawinski A, Prove A, Benoy I, De Pooter C, Martin M and Van Oosterom AT (1997) Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 76: 238-243
13. Dosquet C, Coudert M-C, Lepage E, Cabane J and Richard F (1997) Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res 3: 2451-2458
14. Ferriere JP, Bernard D, Legros M, Chassagne J, Chollet P, Gaillard G and Plagne R (1985) β-Thromboglobulin in patients with breast cancer. Am J Hematol 19: 47-53
15. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6
16. Gasparini G (1996) Angiogenesis research up to 1996. A commentary on the state of art and suggestions for future studies. Eur J Cancer 32A: 2379-2385
17. Handagama PJ, Shuman MA and Bainston DF (1987) Incorporation of intravenously injected albumin, immunoglobulin G, and fibrinogen in guinea pig megakaryocyte granules. J Clin Invest 84: 73-82
18. Harrison P, Wilbourn B, Debili N, Vainchenker W, Breton-Gorius J, Lawrie AS, Masse J-M, Savidge GF and Cramer EM (1989) Uptake of plasma fibrogen into the alpha granules of human megakaryocytes and platelets. J Clin Invest 84: 1320-1324
19. Ishibashi T, Kimura H, Shikama Y, Uchida T, Kariyone S, Hirano T, Kishimoto T, Takatsuki F and Akiyama Y (1989) Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood 74: 1241-1244
20. Jaffe EA, Nachman RL, Becker CG, Minick CR (1973) Culture of human endothelial cells derived from umbilical veins. J Clin Invest 52: 2745-2756
21. Kaushansky K (1995) Thrombopoietin: the primary regulator of platelet production. Blood 86: 419-431
22. Kumar H, Heer K, Lee PWR, Duthie GS, MacDonald AW, Greenman J, Kerin MJ and Monson JRT (1998) Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 4: 1279-1285
23. Lake AM, Stauffer JQ and Stuart MJ (1978) Hemostatic alterations in inflammatory bowel disease: response to therapy. Am J Dig Dis 23: 897-902
24. Liotta LA and Saidel GM (1974) Quantitative relationship of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 34: 997-1004
25. Mateo RB, Reichner JS and Albina JE (1994) Interleukin-6 activity in wounds. Am J Physiol 266: R1840-1844
26. Milroy R, Douglas JT, Campbell J, Carter R, Lowe GD and Banham SW (1988) Abnormal haemostasis in small cell lung cancer. Thorax 43: 978-981
27. Möhle R, Green D, Moore MAS, Nachman RL and Rafii S (1997) Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 94: 663-668
28. Møller Pedersen LM and Milman N (1996) Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J 9: 1826-1830
29. Motro B, Itin A, Sachs L and Keshet E (1990) Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci USA 87: 3092-3096
30. Nakano T, Chaninian AP, Shinjo M, Tonomura A, Miyake M, Togawa N, Ninomiya K and Higashino K (1998) Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. Br J Cancer 77: 907-912
31. Rak JW, Hegmann EJ, Lu C and Kerbel RS (1994) Progressive loss of sensitivity to endothelium-derived growth inhibitors expressed by human melanoma cells during disease progression. J Cell Physiol 159: 245-255
32. Rak J, Filmus J and Kerbel RS (1996) Reciprocal paracrine interactions between tumour cells and endothelial cells: 'angiogenesis progression' hypothesis. Eur J Cancer 32A: 2438-2450
33. Ravoet C, De Grève J, Vandewoude K, Kerger J, Sculier J-P, Lacor P, Stryckmans P and Piccart M (1994) Tumour stimulating effects of recombinant human interleukin-6, Lancet 344: 1576-1577
34. Salven P, Teerenhovi L and Joensuu H (1997) A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 90: 3167-3172
35. Salven P, Ruotsalainen, Mattson K, and Joensuu H (1998) High pretreatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small cell lung cancer. Int J Cancer 79: 144-146
36. Skobe M, Rockwell P, Goldstein N, Vosseler S and Fusenig NE (1997) Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 11: 1222-1227
37. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, Patel S, Reddy SP, Hoots WK, Johnston T, Papadopoulos NE, Hittelman WN, Johnston DA, Yang TA, Paton VE, Cohen RL, Hellmann SD, Benjamin RS and Broxmeyer HE (1997) Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 126: 731-3
38. Verbeul HMW, Hockman K, Luykx-de Bakker S, Eckman CA, Folman CC, Broxterman HJ and Pinedo HM (1997) Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 3: 2187-2190
39. Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL and Dirix LY (1996) Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A: 2474-2484
40. Vermeulen PB, Dirix LY, Martin M, Lemmens J and Van Oosterom AT (1997) The predictive value of serum bFGF and VEGF in patients with metastatic renal cell carcinoma treated with interferon α-2b. J Natl Cancer Inst 89: 1317
41. Wartiovaara U, Salven P, Mikkola H, Lassila R, Kaukonen J, Joukov V, Orpana A, Ristimäki A, Heikinheimo M, Joensuu H, Alitalo K and Palotie A (1998) Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost 80: 171-175
42. Weber J, Yang JC, Topalian SL, Parkinson DR, Schwartzentruber DS, Ettinghausen SE, Gunn H, Mixon A, Kim H and Cole D (1993) Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol 11: 499-506
43. Yazaki T, Inage H, Iizumi T, Koyama A, Kanoh S, Koiso K, Narita M and Tojo S (1987) Studies on platelet function in patients with prostatic cancer. Preliminary report. Urology 30: 60-63
44. Yan SF, Tritto I, Pinsky D, Liao H, Huang J Fuller G, Brett J, May L and Stern D (1995) Induction of interleukin 6 (IL-6) by hypoxia in vascular cells. J Biol Chem 270: 11463-11471